Targeted therapy for refractory PTCL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of targeted drugs, including an EZH2 inhibitor, for people with peripheral T-cell lymphoma that did not respond to initial chemotherapy. It is designed for patients whose tumor has been genetically tested to guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have peripheral T-cell lymphoma that did not respond to at least 3 or 6 cycles of standard chemotherapy.
- If you have anaplastic large cell lymphoma, you must have received brentuximab vedotin as part of your first treatment.
- Your tumor tissue has been genetically analyzed and results are available.
- You are able to care for yourself (ECOG score 0–2) and have a life expectancy of more than 3 months.
- You have adequate organ function and agree to use contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an oral drug (azacytidine) plus romidepsin works better than a standard “doctor’s choice” treatment for people with relapsed or refractory peripheral T-cell lymphoma. It’s for adults whose disease has come back or did not respond after prior treatment.
This trial tests a new drug, Zeprumetostat, in people with a type of lymphoma called PTCL that has come back or not responded to prior treatment. The study looks at how well the drug works and if it is safe.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a new drug combination for people with certain types of lymphoma that have not responded to standard treatments. The drug, zeprumetostat, targets a protein called EZH2 to help stop cancer growth.
This trial tests a combination of three medicines (anti-PD-1, lenalidomide, and azacitidine) for adults with relapsed or refractory peripheral T-cell lymphoma (PTCL) that is measurable or growing. It aims to shrink lymphoma and improve control of the disease when standard treatments haven’t worked or have stopped working.
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.